{
  "catalogId": "dbf7e055-a1f1-4076-a06f-0e794e50f522",
  "name": "ENSPRYNG",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "169 11 36563 00",
  "treatmentDescriptions": "Enspryng is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.",
  "termsOfIssue": "Prescription required",
  "form": "solution for injection",
  "route": "s.c",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "SATRALIZUMAB/",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L04AC19",
      "name": "SATRALIZUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "ENSPRYNG 120MG/ML 1 PREF SYR",
      "manufacturer": {
        "name": "רוש",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "SYRINGE PREFILLED  POLYMER",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "8766"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 27633.22184,
        "retailMargin": 10.0,
        "maxRetailPrice": 30396.54402,
        "maxPriceWithVAT": 35867.92035
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:44.241212"
  }
}